£96.0M
The biotechnology firm has raised £96m in new capital to advance its gene therapy pipeline and manufacturing capabilities.
Freeline
Freeline develops curative gene therapies for chronic systemic diseases.
£96.0MTotal raised
Freeline is a biotechnology company focused on developing curative gene therapies for chronic systemic diseases. The clinical stage business targets liver based AAV gene therapies to provide potential functional cures.
Filed accounts
Net assets
Members only
Shareholders' funds
Members only
Cash, assets and headcount from Freeline's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
Theresa Heggie
CEO
Theresa brings extensive board and executive experience across biotechnology and therapeutics companies. Her career includes serving as chief executive officer at Freeline and interim chief executive officer at Hybridize Therapeutics, alongside multiple board mandates.
LinkedIn